Panelists discuss how emerging therapies—including TKIs, sustained-release implants, and gene therapy—may reduce treatment ...
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...
The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...
Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...
Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...
Zacks.com on MSN
ANIP Stock Rises 7% in a Week: Here's What You Should Know
ANI Pharmaceuticals jumps 7% as 2026 guidance tops expectations, with strong sales and EPS growth fueled by momentum in the ...
Aim for a balanced diet with a variety of foods in order to get enough vitamin E and vitamin K. While sun protection is good, ...
We came across a bullish thesis on Ocular Therapeutix, Inc. on TipRanks’ YouTube channel. In this article, we will summarize ...
Apellis Pharmaceuticals (NASDAQ:APLS) used its presentation at the 44th Annual JPMorgan Healthcare Conference to outline its ...
A woman who lost her vision due to a rare condition before having her sight restored with injections that pumped up her eye has described the treatment as “phenomenal”.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback